Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a trailblazer in targeted radiotherapies, continues to make significant strides in revolutionizing cancer treatment.

On Tuesda, Actinium Pharmaceuticals (NYSE:ATNM) experienced a notable uptick in its stock value on Tuesday, following H.C. Wainwright's commentary on the company's potential attractiveness for acquisitions, especially in the wake of AstraZeneca's (AZN) recent $2.4 billion purchase of Fusion Pharma (FUSN). This acquisition within the radiopharmaceutical industry significantly highlights the growing interest in this sector.

Joseph Pantginis, an analyst from H.C. Wainwright, emphasized the implications of this industry movement for Actinium, especially noting the company's positive momentum in the market following the announcement. Pantginis highlighted Actinium's recent initiative to enhance the production capabilities of Actinium-225, a critical element for its leading experimental cancer treatment, Actimab-A. The rarity and high demand for Ac-225 position it as a coveted resource for the development of targeted radiotherapies.

Facing a landscape of limited supply, Actinium's strategic efforts to increase the availability of Ac-225 not only support its own therapeutic programs but also amplify the company's appeal for potential collaborations and partnerships. With a robust intellectual property portfolio and a focus on advancing radioisotope therapy manufacturing and clinical trials, Actinium is strategically positioned as a prime candidate for mergers and acquisitions within the healthcare sector.

Pantginis, maintaining a Buy rating and setting a price target of $50 per share for ATNM, underscored the significance of Actinium's investment in manufacturing expansion. This move not only bolsters the company's supply of Ac-225 but also highlights its leadership in the radiopharmaceutical space, potentially attracting M&A interest and setting a promising trajectory for Actinium's future endeavors.

Following the remarkable results from the Phase 3 SIERRA trial of Iomab-B, Actinium announced a strategic initiative to manufacture the medical isotope Actinium-225 (Ac-225), leveraging its proprietary cyclotron-based method. This dual-focus on innovative therapies and cutting-edge production technologies positions Actinium at the forefront of oncology advancements.

The SIERRA trial, showcased in oral presentations at the 2024 TCT Meetings, highlighted Iomab-B's unprecedented 100% access to potentially curative bone marrow transplants (BMT) and successful engraftment in patients with active relapsed or refractory acute myeloid leukemia (r/r AML), including those over the age of 65. This patient demographic, often faced with limited treatment options due to high-risk factors, showed improved long-term survival outcomes, marking a significant step forward in addressing unmet patient needs.

Dr. Rajneesh Nath, a leading authority in stem cell transplant and cellular therapy, emphasized the importance of Iomab-B in providing access to potentially curative transplants for older patients with high-risk factors, a group traditionally restricted from BMT due to poor outcomes. Iomab-B's targeted conditioning was well-tolerated, achieving higher rates of complete remission and durable remission, along with improved 1-year and 2-year survival rates, compared to control treatments.

Parallelly, Actinium's announcement to manufacture Ac-225 introduces a game-changing approach to the production of this highly sought-after isotope, known for its alpha-particle emission capable of precisely targeting and eliminating cancer cells. With over 54 international patents and significant technical know-how, Actinium's cyclotron-based production method promises highly pure Ac-225 at a fraction of current costs and higher yields. This initiative not only underscores Actinium's commitment to innovation but also aims to address the growing clinical demand and limited supply of Ac-225, enhancing the company's leadership in alpha-particle therapies.

Sandesh Seth, Actinium's Chairman and CEO, shared the company's vision of leveraging Iomab-B and its proprietary Ac-225 production technology to improve patient outcomes across various segments, including those with treatment-resistant disease and high-risk features. With a strong reception from the medical and scientific communities worldwide, Actinium is focused on making Iomab-B available to patients globally and maximizing the value of its Ac-225 production capabilities through strategic collaborations.

Actinium Pharmaceuticals, Inc., with its advanced pipeline candidates and innovative production methods, is setting new standards in oncology. The company's efforts to meaningfully improve survival for people who have failed existing therapies signify a promising future for targeted radiotherapies, marking Actinium as a key player in the next wave of cancer treatment innovations.

In conclusion, Actinium Pharmaceuticals Inc. (ATNM) is establishing a significant footprint in the realm of targeted radiotherapy through its groundbreaking advancements with Iomab-B and its strategic initiative for the production of Actinium-225. These efforts not only underscore the company's innovative edge but also its pivotal role in addressing critical needs within the oncology sector. With the spotlight on its potential for acquisitions, driven by the industry's growing interest and its own strategic developments, Actinium is poised for continued success. The company's remarkable progress, highlighted by the SIERRA trial's success and its proprietary Ac-225 manufacturing approach, potentially positions Actinium as a leader in the field, ready to leverage its technological and clinical achievements for broader impact. As Actinium Pharmaceuticals strides towards making its therapies globally accessible and enhancing its production capabilities, it remains a beacon of hope and innovation in the fight against cancer, promising a future where targeted radiotherapies play a crucial role in patient care and treatment outcomes.

Among the most active small-cap stocks on Tuesday, Lumen Technologies, Inc. (LUMN) observed a notable increase, closing at $1.7 with a 5.59% rise and a trading volume of 14.61M against its previous 13.81M, showcasing a market cap of $1.72B. Close behind, Cerus Corporation (CERS) surged to $2.04, marking a 9.68% gain with a significant trading volume of 19.70M compared to its average of 1.31M, reflecting a market cap of $369.82M. Li-Cycle Holdings Corp. (LICY) demonstrated remarkable growth, jumping by 22.58% to close at $1.3484, with an explosive trading volume of 92.72M over a usual 6.34M, and a market cap of $241.43M. Microvast Holdings, Inc. (MVST) also experienced a significant uptick, ending at $0.6319 with a 16.54% increase and a trading volume of 11.48M against 3.69M, indicating a market cap of $198.95M. Lastly, NKGen Biotech, Inc. (NKGN) closed at $2.12, up by 7.61%, on a trading volume of 21.94M from 2.47M, showing a market cap of $46.40M. These movements highlight the dynamic nature of the small-cap market, presenting opportunities for investors keen on this segment.


Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated five hundred dollars by a 3rd party Bullzeyemedia LLC for content distribution services on ATNM for March 20th, 2024. We own zero shares of ATNM. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person’s use of or access to this content.

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Phone: (954) 593-5597
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.